Risperidone API Powder CAS 106266-06-2

Risperidone API powder is an antipsychotic medication approved for the treatment of various conditions, including schizophrenia, bipolar I disorder with acute manic or mixed episodes, and autism-associated irritability.

It is used to treat the obvious positive symptoms (such as hallucinations, fantasies, disordered thinking, hostility, suspicion) and obvious negative symptoms (such as slow response, emotional apathy and social apathy, and few words) of acute and chronic schizophrenia and other various psychotic states. It can also alleviate the emotional symptoms related to schizophrenia (such as depression, guilt, and anxiety).

Risperidone API powder is a selective monoaminergic antagonist. It has a high affinity for the 5-hydroxytryptamergic 5-HT2 receptor and the dopaminergic D2 receptor, and can also bind to the α 1-adrenergic receptor. However, its affinity for the H1-histamine receptor and the α 2-adrenergic receptor is relatively low, but it cannot bind to cholinergic receptors. Risperidone is a powerful D2 antagonist, which is the reason why it suppresses positive symptoms of schizophrenia. However, it causes less inhibition of motor function and tonic syncope than classical antipsychotic drugs. The balance of antagonistic effects on serotonin and dopamine in the central nervous system can reduce the occurrence of extrapyramidal reactions. And extend its therapeutic effect to the negative symptoms and emotional symptoms of schizophrenia.